Immucell (ICCC) EBITDA Margin (2010 - 2026)
Immucell's (ICCC) quarterly EBITDA Margin came in at 0.76% in Q4 2025, down 878.0% YoY from 0.1% in Q4 2024, and down 308.45% on a QoQ basis from 0.36% in Q3 2025.
Immucell (ICCC) EBITDA Margin (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of EBITDA Margin data on file, last reported at 0.76% in Q4 2025.
- Quarterly EBITDA Margin fell 878.0% year-over-year to 0.76% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 5.97% (up 1375.0% YoY) and the FY2025 annual result came in at 5.97%, up 1216.0% from the prior year.
- EBITDA Margin slipped to 0.76% in Q4 2025, from 0.36% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 13.85% in Q1 2025 to a low of 2302.22% in Q2 2024.
- A 5-year average of 129.87% and a median of 4.13% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2024 — EBITDA Margin slumped 226530 bps — and 2025, when it surged 231106 bps.
- Tracing ICCC's EBITDA Margin over 5 years: stood at 2.67% in 2021, then sank by 1664 bps to 41.77% in 2022, then surged by 47 bps to 21.94% in 2023, then soared by 137 bps to 8.02% in 2024, then plunged by 109 bps to 0.76% in 2025.
- The last three EBITDA Margin figures came in at 0.76% (Q4 2025), 0.36% (Q3 2025), and 8.84% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Immucell | 92.01 Mn | 83.15 Mn | 2.44 Mn | 26.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.93% |
| Dec 31, 2025 | -0.76% |
| Sep 30, 2025 | 0.36% |
| Jun 30, 2025 | 8.84% |
| Mar 31, 2025 | 13.85% |
| Dec 31, 2024 | 8.02% |
| Sep 30, 2024 | -9.56% |
| Jun 30, 2024 | -2,302.22% |
| Mar 31, 2024 | -4.13% |
| Sep 30, 2023 | -21.94% |
| Jun 30, 2023 | -36.93% |
| Mar 31, 2023 | -65.46% |
| Dec 31, 2022 | -41.77% |
| Sep 30, 2022 | -12.86% |
| Jun 30, 2022 | -16.03% |
| Mar 31, 2022 | 9.51% |
| Dec 31, 2021 | 2.67% |
| Sep 30, 2021 | 5.26% |
| Jun 30, 2021 | 4.74% |
| Mar 31, 2021 | -9.12% |